Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.89
(-2.2%)
HKD 0.89
(-2.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 198.88 Million CNY | 58.37% |
| 2022 | 103.5 Million CNY | 30.07% |
| 2021 | 79.57 Million CNY | -43.61% |
| 2020 | 141.11 Million CNY | 3.18% |
| 2019 | 136.76 Million CNY | 74.89% |
| 2018 | 78.2 Million CNY | 5.04% |
| 2017 | 74.44 Million CNY | 59.08% |
| 2016 | 46.79 Million CNY | -48.43% |
| 2015 | 90.75 Million CNY | -17.22% |
| 2014 | 109.63 Million CNY | 152.86% |
| 2013 | 43.35 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 103.04 Million CNY | 631.87% |
| 2023 Q2 | 147.6 Million CNY | 790.33% |
| 2023 FY | 163.92 Million CNY | 58.37% |
| 2023 Q4 | 14.07 Million CNY | -90.46% |
| 2022 FY | 103.5 Million CNY | 30.07% |
| 2022 Q2 | 86.92 Million CNY | 2680.77% |
| 2022 Q4 | 16.57 Million CNY | -80.93% |
| 2021 FY | 79.57 Million CNY | -43.61% |
| 2021 Q2 | 76.45 Million CNY | 33.13% |
| 2021 Q4 | 3.12 Million CNY | -95.91% |
| 2020 Q2 | 83.69 Million CNY | 27.87% |
| 2020 FY | 141.11 Million CNY | 3.18% |
| 2020 Q4 | 57.42 Million CNY | -31.39% |
| 2019 FY | 136.76 Million CNY | 74.89% |
| 2019 Q4 | 65.45 Million CNY | -8.22% |
| 2019 Q2 | 71.31 Million CNY | 138.02% |
| 2018 Q2 | 48.24 Million CNY | 47.85% |
| 2018 FY | 78.2 Million CNY | 5.04% |
| 2018 Q4 | 29.96 Million CNY | -37.89% |
| 2017 Q2 | 41.81 Million CNY | 155.4% |
| 2017 Q4 | 32.62 Million CNY | -21.98% |
| 2017 FY | 74.44 Million CNY | 59.08% |
| 2016 Q4 | 16.37 Million CNY | -46.18% |
| 2016 FY | 46.79 Million CNY | -48.43% |
| 2016 Q2 | 30.42 Million CNY | 124.81% |
| 2015 Q4 | 13.53 Million CNY | -82.47% |
| 2015 Q2 | 77.22 Million CNY | 53.96% |
| 2015 FY | 90.75 Million CNY | -17.22% |
| 2014 FY | 109.63 Million CNY | 152.86% |
| 2014 Q2 | 59.48 Million CNY | 105.44% |
| 2014 Q4 | 50.15 Million CNY | -15.68% |
| 2013 FY | 43.35 Million CNY | 0.0% |
| 2013 Q4 | 28.95 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -39.067% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 92.533% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 2536.694% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -386.504% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 481.126% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -451.809% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 35.912% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 401.128% |
| SSY Group Limited | 1.63 Billion HKD | 87.865% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -14.166% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 40.298% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 98.363% |